title: Review of the rational use and adverse reactions to human serum albumin in the People's Republic of China.
abstract: Human serum albumin (HSA) is an ideal natural colloid that has been widely used in clinical practice for supplemental albumin or as a plasma substitute during therapeutic plasma exchanges to redress hypoproteinemia. However, a paucity of well-designed clinical trials, a lack of a clear cut survival benefit, and frequent case reports of adverse drug reaction (ADR) make the use of HSA controversial. This study aims to review and to comment on the reported ADRs of HSA in the People's Republic of China, so as to provide the basis for rational HSA use in clinical settings. Data on the ADR case reports from HSA administration between January 1990 and December 2012 available from the China National Knowledge Infrastructure (CNKI) database, Wanfang data (WF), and Chinese Biomedical Literature (CBM) were reviewed. The reasons for using HSA, the types of ADRs, the causality of ADRs and the rationality for HSA administration were extracted and analyzed. In total, 61 cases of ADR reports were identified of which the primary disease of patients using HSA was malignant tumor (34.42%). The primary ADR was anaphylaxis (59.02%). Of the 61 cases, 30 were caused by irrational use of HSA. The most common irrational use was off-label use (56.67%), followed by inappropriate infusion rate. Therefore, we conclude that to avoid the occurrence of ADRs, guidelines for using HSA are needed to guarantee its rational use and HSA should be used strictly according to these guidelines. In addition, medical staff, including clinical pharmacists and nurses, should pay more attention to the patients who inject HSA to ensure its safe use in the clinic.
authors.affiliation: Department of Clinical Pharmacology, Fengxian Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
authors.forename: Ting
authors.initials: T
authors.lastname: Zhou
authors.affiliation: Department of Clinical Pharmacology, Fengxian Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
authors.forename: Saihua
authors.initials: S
authors.lastname: Lu
authors.affiliation: Department of Clinical Pharmacology, Fengxian Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
authors.forename: Xiufeng
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Clinical Pharmacology, Fengxian Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
authors.forename: Ye
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Clinical Pharmacology, Fengxian Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
authors.forename: Feng
authors.initials: F
authors.lastname: Xu
keywords: ADR; HSA; albumin; hypoproteinemia; off-label use; plasma substitute